Biotechnology News and Research

RSS

Study reveals potential opportunity for sponsors to reduce costs

A recent study by Cutting Edge Information focusing on compensation levels for clinical investigators reveals a potential opportunity for sponsors to reduce costs.

13 Jan 2010

Study indicates public and private funding for US biomedical research has decreased substantially

The rate of increase for funding of biomedical research in the U.S. has slowed since 2005, and the level of funding from the National Institutes of Health and industry appears to have decreased by 2 percent in 2008, after adjustment for inflation, according to an article in the January 13 issue of JAMA.

13 Jan 2010

New search and data mining tools used to find information held by UKPMC launched

The British Library has showcased a range of new search and data mining tools which can be used to find information held by UK PubMed Central (UKPMC).

13 Jan 2010

Monsanto and Stokes Bio announce licensing agreement and R&D collaboration

Monsanto Company and Limerick-based biotechnology firm, Stokes Bio Limited, announced today that they have entered into a licensing agreement and R&D collaboration, which is expected to help accelerate the pace of new advancements in plant breeding.

13 Jan 2010

ProtoKinetix’ AAGP raises hope for treatment of diabetes

Independent studies done by universities and corporations have illustrated a remarkable increase in the yield of viable stem cells after cryopreservation using AAGP™ in the freeze-thaw process. One future approach to increasing diabetics’ insulin production is related to an ability to convert their stem cells into islet cells for transplantation. The feasibility of this procedure is dependent upon the amount of functioning islet cells that can be derived from the patient’s stem cells. This is where AAGP™ can make a very beneficial contribution.

13 Jan 2010

moksha8 receives approval to import and use peramivir in patients with H1N1 influenza A in Mexico

moksha8 and BioCryst today announced that moksha8 has been granted approval from COFEPRIS (The Federal Commission for the Protection against Sanitary Risk) in Mexico for the importation and use of peramivir in patients with influenza associated with the 2009 H1N1 influenza A strain.

13 Jan 2010

Donald Danforth Plant Science Center researchers enter into research collaboration with Dow AgroSciences

Researchers working at the Donald Danforth Plant Science Center have entered into a research collaboration with Dow AgroSciences LLC, a wholly owned subsidiary of The Dow Chemical Company, to study how its EXZACTTM Precision Technology can help improve the root crop cassava for millions of people living in developing countries.

13 Jan 2010

Spectrum Pharmaceuticals achieves its enrollment target in second of two apaziquone Phase 3 trials

Spectrum Pharmaceuticals today announced that the second of two Phase 3 pivotal clinical trials of apaziquone has achieved its enrollment target. The two trials enrolled more than 1600 patients with non-muscle invasive bladder cancer. As per the collaboration agreement with Allergan, a $1.5 million milestone payment will be paid to Spectrum Pharmaceuticals.

13 Jan 2010

Microbix Biosystems signs partnership agreement with Therapure Biopharma

Microbix Biosystems Inc., a biotechnology company focused on virology and biological technologies, and Therapure Biopharma Inc., an integrated biopharmaceutical company that develops, manufactures, purifies and packages therapeutic proteins, announced today the signing of a partnership agreement to manufacture and market water-based products to the pharmaceutical, biotechnology and other industries.

13 Jan 2010

NOVAVAX completes pre-clinical safety and efficacy study of its RSV vaccine candidate

Novavax, Inc. announced today that it has successfully completed a pre-clinical safety and efficacy study of its RSV vaccine candidate in cotton rats. Results from this study are needed to support an Investigational New Drug (IND) application to advance this novel recombinant F protein particle based RSV (RSV-F) vaccine candidate into clinical development. This vaccine candidate is composed of recombinant 'F' or 'fusion' protein of RSV which is used by the virus to infect and fuse with cells in the respiratory tract and cause disease.

13 Jan 2010

Patient enrollment in Spherix's global Phase 3 clinical trial NEET completed

Spherix Inc., an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced the completion of patient enrollment in its global Phase 3 clinical trial NEET (70971-004), which is evaluating the safety and efficacy of D-tagatose as an oral treatment for Type 2 diabetes mellitus.

12 Jan 2010

TD2 and COTI work together to obtain approval of clinical trials for COTI-2

TGen Drug Development (TD2) and Critical Outcome Technologies Inc. (COTI) (TSXV:COT) announced today that they will work together to obtain approval of clinical trials for a promising new anti-cancer drug called COTI-2.

12 Jan 2010

Pall acquires U.S. biotechnology company

Pall Corporation, a global leader in filtration, separation and purification, today announced its acquisition of MicroReactor Technologies, Inc. (MRT), a privately held U.S. biotechnology company. MRT has developed a reliable, easy-to-use and cost-effective miniature bioreactor technology platform.

From Pall Corporation 12 Jan 2010

TTI enters into definitive license agreement with Biogen Idec

Trillium Therapeutics Inc. , a biopharmaceutical company developing innovative immune-based biologics, today announced that it has entered into a definitive license agreement with Biogen Idec , granting the latter exclusive worldwide rights to one of Trillium's development programs.

12 Jan 2010

VaxInnate grants license to Biological E. to develop and commercialize recombinant H1N1 vaccine in India

VaxInnate Corporation today announced that it has granted Indian biopharmaceutical company Biological E. Limited a license to its recombinant H1N1 pandemic swine flu vaccine and is collaborating to facilitate the manufacture, clinical development and commercialization of the vaccine in India.

12 Jan 2010

Life Technologies to acquire AcroMetrix

Life Technologies Corporation, a provider of innovative life science solutions, today announced that it has signed a definitive agreement to acquire AcroMetrix, for an undisclosed amount.

12 Jan 2010

ALS TDI to receive grant of $1.6M for research and development of potential therapeutics for ALS

In recognition of multiple studies connecting ALS to military service, the 2010 Defense Appropriations Act, signed by President Obama on December 22, 2009, provided for the grant of $1.6 million for research and development of potential therapeutics for Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig's disease).

12 Jan 2010

Evidence-based care for lung cancer patients results in an average cost savings of 35%, says study

A study recently conducted by US Oncology and Aetna finds that evidence-based care for patients with non-small cell lung cancer (NSCLC) results in an average cost savings of 35 percent over 12 months while demonstrating equivalent health outcomes. The study, which compared patients treated with evidence-based guidelines (also known as ‘on pathway’) to those treated with non-evidence-based guidelines (also known as ‘off pathway’), was published in the peer-reviewed Journal of Oncology Practice.

12 Jan 2010

miRagen Therapeutics establishes SAB

miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced today the formation of the company’s world renowned Scientific Advisory Board (SAB). The SAB was established to provide miRagen with valuable guidance in developing an extensive pipeline of microRNA-based drugs and is comprised of leaders who are internationally recognized experts in their respective fields.

12 Jan 2010

VentiRx Pharmaceuticals completes $25 million Series A Extension

VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 (TLR8) candidates for the treatment of cancer, respiratory and inflammatory diseases, announced today the completion of a $25 million Series A Extension.

12 Jan 2010

Biotechnology News and Research

Study reveals potential opportunity for sponsors to reduce costs

Study indicates public and private funding for US biomedical research has decreased substantially

New search and data mining tools used to find information held by UKPMC launched

Monsanto and Stokes Bio announce licensing agreement and R&D collaboration

ProtoKinetix’ AAGP raises hope for treatment of diabetes

moksha8 receives approval to import and use peramivir in patients with H1N1 influenza A in Mexico

Donald Danforth Plant Science Center researchers enter into research collaboration with Dow AgroSciences

Spectrum Pharmaceuticals achieves its enrollment target in second of two apaziquone Phase 3 trials

Microbix Biosystems signs partnership agreement with Therapure Biopharma

NOVAVAX completes pre-clinical safety and efficacy study of its RSV vaccine candidate

Patient enrollment in Spherix's global Phase 3 clinical trial NEET completed

TD2 and COTI work together to obtain approval of clinical trials for COTI-2

Pall acquires U.S. biotechnology company

TTI enters into definitive license agreement with Biogen Idec

VaxInnate grants license to Biological E. to develop and commercialize recombinant H1N1 vaccine in India

Life Technologies to acquire AcroMetrix

ALS TDI to receive grant of $1.6M for research and development of potential therapeutics for ALS

Evidence-based care for lung cancer patients results in an average cost savings of 35%, says study

miRagen Therapeutics establishes SAB

VentiRx Pharmaceuticals completes $25 million Series A Extension

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News